ARCHIVES
This 2 stage study will investigate the effectiveness and safety of a combination pharmacotherapy for methamphetamine use disorder. Stage 1 will include 20 participants with moderate or severe stimulant use disorder who will receive a monthly injection of extended-release depot naltrexone plus once-daily bupropion extended-release tablets for 8 weeks. If Stage 1 data documents success in at least 3 “responder” study participants, Stage 2 will follow utilizing the same protocol as in Stage 1, to enroll an additional group of 29 participants.
CTN Protocol ID:
CTN-0054
Enrollment Status:
Completed
ClinicalTrials.gov ID:
Principal Investigator(s):
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu
Participating Sites
- Integrated Substance Abuse Programs, California
- University of Hawaii, Hawaii
- Nexus Recovery Center, Inc., Texas
